Multiple Myeloma in Relapse research hub
6 indexed studies · 6 currently recruiting
- recruitingNA
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
This study looks at adding early support care for people with multiple myeloma or aggressive lymphoma. It wants to see if this helps improve their well-being, mood, and how they feel about their care, compared to standard care alone.
Canada - enrolling by invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
This study looks at the long-term effects of AvenCell's CAR-T cell treatments for blood cancers like lymphoma and leukemia, and also prostate cancer. It checks how safe and effective these treatments are over time for people who've already had them in past AvenCell trials.
Germany - recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
This study is looking at a new combination of medicines, sonrotoclax plus zanubrutinib, for adults in the UK with a type of blood cancer called Mantle Cell Lymphoma. It aims to see if this combination works better and is safe when their cancer has come back or isn't responding to other treatments.
United States · Argentina · Australia - recruitingPHASE1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This study is testing a new drug, LY4152199, for people with certain types of B-cell lymphoma that have returned or not responded to previous treatments. Researchers want to find the best dose and see how safe and effective it is.
United States · Australia · Canada - recruitingPHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new medicine, IKS03, for people with certain types of advanced B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see how well it works. This is an early-stage study, meaning it's the first time it’s being given to people.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
This study looks at a new drug, BGB-16673, combined with other medicines for people with B-cell cancers that have come back or not responded to past treatments. It checks how safe and effective these combinations are.
United States · Australia · Brazil